Steven D. Harr
2016 - Juno Therapeutics
In 2016, Steven D. Harr earned a total compensation of $2.9M as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, a 15% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $131,840 |
|---|---|
| Option Awards | $2,378,863 |
| Salary | $404,954 |
| Total | $2,915,657 |
Harr received $2.4M in option awards, accounting for 82% of the total pay in 2016.
Harr also received $131.8K in non-equity incentive plan and $405K in salary.
Rankings
In 2016, Steven D. Harr's compensation ranked 3,298th out of 14,075 executives tracked by ExecPay. In other words, Harr earned more than 76.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,298 out of 14,075 | 77th |
Division Manufacturing | 1,142 out of 5,489 | 79th |
Major group Chemicals And Allied Products | 340 out of 1,895 | 82nd |
Industry group Drugs | 246 out of 1,538 | 84th |
Industry Biological Products, Except Diagnostic Substances | 51 out of 279 | 82nd |
Source: SEC filing on April 21, 2017.
Harr's colleagues
We found four more compensation records of executives who worked with Steven D. Harr at Juno Therapeutics in 2016.
News
Sana Biotechnology Former Executive Vice President and President, Research and Development Douglas Williams receives $3M in 2023
April 26, 2024
Sana Biotechnology General Counsel Bernard Cassidy receives $4M in 2022
April 28, 2023
Sana Biotechnology Chief Medical Officer Sunil Agarwal receives $1.9M in 2021
April 26, 2022